ALPHACENTRIC ADVISORS LLC
Q2 2026 Form 13-F
SAN JUAN, PUERTO RICO
CIK 0001913464
· CRD 170679
· SEC-registered investment adviser
$118.0M Reported Value Total
ALPHACENTRIC ADVISORS LLC reports 6 total accounts under management (AUM). There are 6 discretionary accounts valued at $433,084,612, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Source: Form ADV filed 2026-06-02
Reported value
$118.0M
Quarter over quarter
+11.6%
Holdings
259
Top-10 concentration
16.3%
Key People
Form ADV owners & control persons
David Scott Miller
MEMBER
Jerry John Szilagyi
MANAGING MEMBER
Michael Thomas Schoonover
MEMBER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2026 13F record
Q2 2026 13F filing summary
| Period of report | June 30, 2026 |
|---|---|
| Filed | July 24, 2026 |
| Form | 13F-HR |
| Reported value | $118.0M |
| Positions | 259 |
| Change in reported value | +17.9% |
| New positions | 35 |
| Exited positions | 28 |
| Position turnover | 22.0% |
| Top-10 concentration | 16.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 3, 2026
|
245 | $112.6M |
|
Q2 2026 13F
Filed Jul 24, 2026
|
259 | $118.0M |
|
Q1 2026 13F
Filed May 7, 2026
|
252 | $100.1M |
|
Q4 2025 13F
Filed Feb 12, 2026
|
249 | $100.3M |
|
Q4 2024 13F
Filed Jan 31, 2025
|
209 | $100.2M |
|
Q3 2024 13F
Filed Oct 30, 2024
|
230 | $134.5M |
|
Q2 2024 13F
Filed Jul 25, 2024
|
217 | $135.8M |
|
Q1 2024 13F
Filed Apr 24, 2024
|
228 | $165.8M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
216 | $149.0M |
|
Q3 2023 13F
Filed Nov 13, 2023
|
234 | $176.3M |
|
Q2 2023 13F
Filed Aug 8, 2023
|
231 | $180.2M |
|
Q1 2023 13F
Filed May 12, 2023
|
209 | $144.9M |
|
Q4 2022 13F
Filed Feb 7, 2023
|
165 | $101.2M |
|
Q3 2022 13F
Filed Nov 8, 2022
|
184 | $97.4M |
|
Q4 2021 13F
Filed Feb 25, 2022
|
220 | $343.1M |
6 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | GILD GILEAD SCIENCES INC | $2.6M | 2.19% |
| 2 | VRTX VERTEX PHARMACEUTICALS INC | $2.5M | 2.11% |
| 3 | INVH INVITATION HOMES INC | $2.2M | 1.87% |
| 4 | AZN ASTRAZENECA PLC | $2.2M | 1.83% |
| 5 | ROIV ROIVANT SCIENCES LTD | $1.7M | 1.45% |
| 6 | ARGX ARGENX SE | $1.7M | 1.42% |
| 7 | NBIX NEUROCRINE BIOSCIENCES INC | $1.6M | 1.39% |
| 8 | INCY INCYTE CORP | $1.6M | 1.39% |
| 9 | AXSM AXSOME THERAPEUTICS INC. | $1.6M | 1.35% |
| 10 | APGE APOGEE THERAPEUTICS INC | $1.5M | 1.3% |
| 11 | EEFT EURONET WORLDWIDE INC | $1.5M | 1.24% |
| 12 | AEVA AEVA TECHNOLOGIES INC | $1.4M | 1.22% |
| 13 | IWD ISHARES TR | $1.4M | 1.19% |
| 14 | RPV INVESCO EXCHANGE TRADED FD T | $1.4M | 1.17% |
| 15 | QQQ INVESCO QQQ TR | $1.4M | 1.16% |
| 16 | QQQM INVESCO EXCH TRADED FD TR II | $1.4M | 1.16% |
| 17 | BFS SAUL CTRS INC | $1.3M | 1.11% |
| 18 | INSM INSMED INC | $1.2M | 1.06% |
| 19 | IONS IONIS PHARMACEUTICALS INC | $1.2M | 1.04% |
| 20 | ASND ASCENDIS PHARMA A/S | $1.2M | 1.04% |
Values as reported on the Q2 2026 Form 13F. Every position is in the holdings table below.